Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515399 | 0.87 | NOTUM (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL15311690 | 0.87 | GPR52 (0.31) | — | |
| SCHEMBL8515471 | 0.86 | NOTUM (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL8514315 | 0.84 | LMNA (0.37) | LMNAGAATSPOSMN1; SMN2 | |
| SCHEMBL15317616 | 0.84 | CHRM1 (0.32) | LMNAGAATSPO | |
| SCHEMBL8532961 | 0.83 | PTGS2 (0.40) | — | |
| SCHEMBL8515390 | 0.83 | MAPK1 (0.32) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL8512403 | 0.81 | MAPT (0.33) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL14816084 | 0.81 | NR1I2 (0.32) | GAA | |
| SCHEMBL8512307 | 0.81 | KIF11 (0.33) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643324-B1 | ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2643324-B1 | ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-9040523-B2 | Antifungal 5,6-dihydro-4H-pyrrolo[1,2-α][1,4]-benzodiazepines and 6H-pyrrolo[1,2-α][1,4]benzodiazepines substituted with benzene derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-9040523-B2 | Antifungal 5,6-dihydro-4H-pyrrolo[1,2-α][1,4]-benzodiazepines and 6H-pyrrolo[1,2-α][1,4]benzodiazepines substituted with benzene derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-9040523-B2 | Antifungal 5,6-dihydro-4H-pyrrolo[1,2-α][1,4]-benzodiazepines and 6H-pyrrolo[1,2-α][1,4]benzodiazepines substituted with benzene derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20130274250-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BENZENE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274250-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BENZENE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274250-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BENZENE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| EP-2643324-A1 | ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069380-A1 | ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069380-A1 | ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274250-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BENZENE DERIVATIVES | GABBR1, GABBR2, CYP1B1 | LMNA 4506/4885GAA 1934/4885TSPO 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.